Back to Journals » OncoTargets and Therapy » Cancer Immunotherapy: Harnessing the Immune System for Cancer Treatments
OncoTargets and Therapy
ISSN: 1178-6930
- View all (6517)
- Volume 17, 2024 (79)
- Volume 16, 2023 (147)
- Volume 15, 2022 (191)
- Volume 14, 2021 (525)
- Volume 13, 2020 (1171)
- Volume 12, 2019 (1075)
- Volume 11, 2018 (882)
- Volume 10, 2017 (615)
- Volume 9, 2016 (802)
- Volume 8, 2015 (439)
- Volume 7, 2014 (253)
- Volume 6, 2013 (208)
- Volume 5, 2012 (54)
- Volume 4, 2011 (19)
- Volume 3, 2010 (22)
- Volume 2, 2009 (25)
- Volume 1, 2008 (10)
Journal Articles:
Cancer Immunotherapy: Harnessing the Immune System for Cancer Treatments
In the last decade, harnessing the immune system with immune checkpoint blockades has achieved remarkable results in solid tumors of different histotypes, enabling durable responses and long-term survival. Despite these unprecedented results, primary or acquired resistance can limit its efficacy; therefore a deeper understanding of the underlying mechanism of resistance is crucial for the identification of novel therapeutic strategies in several clinical settings (e.g. adjuvant, neo-adjuvant setting, rare tumors, etc.). In this exciting scenario, to untangle the threads of immunotherapy, research needs to answer some key questions, ranging from the mechanistic exploration causing lack of response, to the identification of biomarkers, but also the development of novel immunotherapeutic modalities and their clinical applications.
Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report
Yan J, Zhang X, Yu L, Ye M, Chen Y
OncoTargets and Therapy 2024, 17:287-295
Published Date: 3 April 2024
Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer
Chen L, Meng Z, Zhou Z, Li X, Zhao L, Jia Z, Chen J, Tian Y, Meng Q, Liu Y
OncoTargets and Therapy 2023, 16:885-890
Published Date: 30 October 2023